Abstract
A transient deterioration in neurological status following commencement of chemotherapy for high-grade gliomas has not been previously described. We report eight cases of transient deterioration following administration of temozolomide, a relatively new cytotoxic agent used in the treatment of high-grade gliomas. We believe this represents the novel clinical entity of temozolomide-induced tumour flare.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Alkylating / adverse effects*
-
Astrocytoma / drug therapy
-
Astrocytoma / pathology
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / pathology*
-
Brain Neoplasms / physiopathology
-
Dacarbazine / administration & dosage
-
Dacarbazine / adverse effects*
-
Dacarbazine / analogs & derivatives*
-
Female
-
Glioblastoma / drug therapy
-
Glioblastoma / pathology
-
Glioma / drug therapy*
-
Glioma / pathology*
-
Glioma / physiopathology
-
Humans
-
Karnofsky Performance Status
-
Male
-
Middle Aged
-
Prognosis
-
Retrospective Studies
-
Risk Factors
-
Severity of Illness Index
-
Temozolomide
Substances
-
Antineoplastic Agents, Alkylating
-
Dacarbazine
-
Temozolomide